VivoSeq
Other

Pneumococcal Disease

3

Pipeline Programs↗

5

Active Trials↗

3

Companies Involved↗

Pneumococcal Disease is an early-stage landscape with 3 programs across 3 companies. The most active players are Merck & Co., Pfizer, GSK. 1 therapy is approved with 1 more in late-stage development.

Intelligence

Pipeline Metrics

Competitive Density

28/100

Pipeline Velocity

19/100

Mech. Concentration

N/A

Completion Rate

100/100

Attrition Rate

0/100

Competition

Competitive Landscape

Bubble size = clinical trials

Approved
Phase 3
Phase 2
Phase 1
Preclinical

Key Players

Top Companies Companies ranked by the number of pipeline programs they run for this disease.

Merck & Co. logo

Merck & Co.

1 program

Phase 2Pfizer logo

Pfizer

2 programs

Phase 3GSK logo

GSK

1 program

Approved

Pipeline

Programs by Phase

Preclinical
No programs
Phase 1
No programs
Phase 21

PCV15

Merck & Co.

Phase 31

PG4

Pfizer

Approved1

Pneumococcal Vaccine

GSK

Analysis

Trial Status

8

clinical trials

Recruiting4 · 50%
Completed2 · 25%
Unknown status1 · 13%
Active, not recruiting1 · 13%

Clinical Trials

Trial Activity

8 trials

A PHASE 3, RANDOMIZED, DOUBLE-BLINDED TRIAL TO EVALUATE THE SAFETY AND TOLERABILITY OF A MULTIVALENT PNEUMOCOCCAL CONJUGATE VACCINE IN HEALTHY INFANTS
Recruiting·Pfizer logoPfizer·Phase 3·NCT07573462·2,400 enrolled
Novel Serotype Alert: Investigate New Pneumococcal Conjugate Vaccines for Inducing Cross-protection Against Newly Discovered Serotype 33E and Putative Novel Serogroup 33 Serotypes
Recruiting·UUniversity of Alabama at Birmingham·Approved·NCT07135453·70 enrolled
A PHASE 3, RANDOMIZED DOUBLE-BLIND TRIAL TO EVALUATE THE SAFETY, TOLERABILITY, AND IMMUNOGENICITY OF A CATCH-UP VACCINATION REGIMEN OF A MULTIVALENT PNEUMOCOCCAL CONJUGATE VACCINE IN HEALTHY CHILDREN AND ADOLESCENTS
Recruiting·Pfizer logoPfizer·Phase 3·NCT07660198·1,200 enrolled
A PHASE 3, RANDOMIZED, DOUBLE-BLIND TRIAL TO EVALUATE THE SAFETY, TOLERABILITY, AND IMMUNOGENICITY OF A MULTIVALENT PNEUMOCOCCAL CONJUGATE VACCINE IN HEALTHY INFANTS
Recruiting·Pfizer logoPfizer·Phase 3·NCT07629440·3,230 enrolled
A Phase 2, Randomized, Double-Blind Trial to Evaluate the Safety, Tolerability, and Immunogenicity of a Multivalent Pneumococcal Conjugate Vaccine in Healthy Infants
Active, not recruiting·Pfizer logoPfizer·Phase 2·NCT06524414·605 enrolled
Safety and Immunogenicity of V116 in Adults With Increased Risk for Pneumococcal Disease (V116-008)
Completed·Merck & Co. logoMerck & Co.·Phase 3·NCT05696080·518 enrolled
A Study to Evaluate the Safety, Tolerability, and Immunogenicity of V114 Followed by PNEUMOVAX™23 in Adults at Increased Risk for Pneumococcal Disease (V114-017/PNEU-DAY)
Completed·Merck & Co. logoMerck & Co.·Phase 3·NCT03547167·1,515 enrolled
PREVENTING PNEUMOcoccal Disease Through Vaccination (Study 2)
Unknown status·LLiverpool School of Tropical Medicine·Phase 4·NCT04974294·516 enrolled

Data sources: ClinicalTrials.gov (NIH) · OpenFDA (FDA) · ChEMBL (EMBL-EBI) · Open Targets (EBI/Sanger) · MedlinePlus (NIH) · PubMed (NIH) · SEC EDGAR (SEC)